Treatment challenges and optimal management of classical Hodgkin’s lymphoma

VernacularTitle:经典型霍奇金淋巴瘤的治疗挑战与优化
Author: Jianqing MI ¹ ; Yu FANG ; Wenyan YU ; Qingqing CAI
Author Information

1. 上海血液学研究所，医学基因组学国家重点实验室，国家转化医学中心（上海），上海交通大学医学院附属瑞金医院，上海　200025
Publication Type:Journal Article
From: Chinese Journal of Hematology 2025;46(4):364-371
CountryChina
Language:Chinese
Abstract: The cure rate of patients with classical Hodgkin’s lymphoma (cHL) has significantly improved and the mortality rate has decreased with the advancement of chemotherapy and radiotherapy, especially the application of combined radio-chemotherapy. However, some patients still face relapse or refractory issues, as well as the risk of death due to treatment-related adverse reaction. Treatment has fully entered the era of targeted therapy in recent years, with the deepening research on cHL. Novel drugs, represented by targeted CD30 antibody-drug conjugates and immune checkpoint inhibitors, have further improved the prognosis of patients with newly diagnosed and relapsed/refractory cHL. This study aims to determine the mechanism of achieving comprehensive optimization management of cHL in the new era of drugs, improve patient prognosis, enhance therapeutic efficacy, and reduce the occurence of adverse reactions.